NCT04175743View on ClinicalTrials.gov

Double-blind, Placebo-control, Study to Evaluate the Safety and Pharmacokinetics of CT-044 HCl, in Healthy Volunteers

PHASE1UnknownINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

December 4, 2019

Primary Completion Date

August 31, 2020

Study Completion Date

September 30, 2020

Conditions
Acute PainPain, AcuteSurgeryNeuropathy
Interventions
DRUG

CT-044 HCl

CT-044 HCl is a reactive species decomposition accelerant

Trial Locations (1)

91105

Lotus Clinical Resarch,LLC, Pasadena

Sponsors

Collaborators (1)

CerSci Therapeutics
All Listed Sponsors
collaborator

CerSci Therapeutics

UNKNOWN

lead

Lotus Clinical Research, LLC

OTHER

NCT04175743 - Double-blind, Placebo-control, Study to Evaluate the Safety and Pharmacokinetics of CT-044 HCl, in Healthy Volunteers | Biotech Hunter | Biotech Hunter